Form 4: REGENXBIO Inc. Executive Steve Pakola Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer Steve Pakola reports acquisition and disposal of REGENXBIO Inc. stock and stock options.
Summary
- On January 2, 2025, Steve Pakola, Chief Medical Officer of REGENXBIO Inc., reported transactions involving the company's stock.
- Pakola disposed of 13,891 shares of common stock at $7.73 per share to cover taxes related to vesting restricted stock units.
- He also acquired 64,293 shares of common stock underlying a time-based restricted stock unit award.
- Additionally, Pakola acquired options to purchase 103,698 shares of common stock at an exercise price of $7.86.
- Following these transactions, Pakola directly owns 215,980 shares of common stock and options to purchase 103,698 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment. The transactions are part of standard executive compensation and don't necessarily indicate a strong positive or negative outlook.
Positives
- The acquisition of restricted stock units and stock options indicates confidence in the company's future performance.
Future Outlook
The vesting schedules for the restricted stock units and stock options extend to January 2029 and January 2035, respectively, indicating a long-term commitment from the executive.
Industry Context
Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's prospects. Acquisition of shares and options can be seen as a positive signal.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology industry.
- Vesting schedules of 3-4 years are typical to incentivize long-term performance.
- Comparing the size of the grant to those of executives at similar-sized biotech companies (e.g., companies with similar market capitalization and pipeline stage) would provide further context.
Stakeholder Impact
- The transactions may have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.
Key Dates
| Date | Description |
|---|---|
| 01/04/2021 | Date of original grant of restricted stock units. |
| 01/03/2022 | Date of original grant of restricted stock units. |
| 01/03/2023 | Date of original grant of restricted stock units. |
| 01/02/2024 | Date of original grant of restricted stock units. |
| 12/31/2024 | Date used to determine the closing price of the issuer's common stock for tax withholding. |
| 01/02/2025 | Date of the reported transactions (stock disposal and acquisition of RSUs and options). |
| 01/02/2025 | Stock Options (Right to buy) Aquisition Date |
| 01/06/2025 | Date of signature on the Form 4 filing. |
| 01/01/2026 | First vesting date for 25% of the restricted stock units. |
| 01/02/2026 | First vesting date for 25% of the stock options. |
| 01/01/2027 | Second vesting date for 25% of the restricted stock units. |
| 01/01/2028 | Third vesting date for 25% of the restricted stock units. |
| 01/01/2029 | Final vesting date for 25% of the restricted stock units. |
| 01/02/2035 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.